Enliven Therapeutics
ELVN
34 hedge funds and large institutions have $302M invested in Enliven Therapeutics in 2020 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 7 closing their positions.
243% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 7
100% more funds holding
Funds holding: 17 → 34 (+17)
73% more capital invested
Capital invested by funds: $174M → $302M (+$128M)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
0.56% less ownership
Funds ownership: 16.38% → 15.82% (-0.56%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.4M |
| 2 |
BlackRock
New York
|
+$9.59M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.46M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.3M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$17.5M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$4.12M |
| 3 |
Morgan Stanley
New York
|
-$3.9M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$2.27M |
| 5 |
DM
Deerfield Management
New York
|
-$2.13M |
ELVN Hedge Fund Activity: Q2 2020 in Review
34 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q2 2020, worth a combined $302M — up 73% from $174M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ELVN positions and 7 closed out — a net gain of 17 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $16.4M. The largest seller was RA Capital Management, cutting an estimated $17.5M.
- 34 institutional investors held Enliven Therapeutics (ELVN) as of Q2 2020, up from 17 in Q1 2020.
- Funds reported $302M of Enliven Therapeutics stock for Q2 2020, up 73% quarter-over-quarter.
- 24 funds opened new Enliven Therapeutics positions in Q2 2020 and 7 closed out, a net change of +17 holders.
- The largest Enliven Therapeutics buyer in Q2 2020 was Fidelity Investments, an estimated $16.4M added.
- The largest Enliven Therapeutics seller in Q2 2020 was RA Capital Management, an estimated $17.5M sold.
Based on aggregated 13F filings for Q2 2020.